Hastings-Levitov aggregation in the small-particle limit

We establish some scaling limits for a model of planar aggregation. The model is described by the composition of a sequence of independent and identically distributed random conformal maps, each corresponding to the addition of one particle. We study the limit of small particle size and rapid aggregation. The process of growing clusters converges, in the sense of Caratheodory, to an inflating disc. A more refined analysis reveals, within the cluster, a tree structure of branching fingers, whose radial component increases deterministically with time. The arguments of any finite sample of fingers, tracked inwards, perform coalescing Brownian motions. The arguments of any finite sample of gaps between the fingers, tracked outwards, also perform coalescing Brownian motions. These properties are closely related to the evolution of harmonic measure on the boundary of the cluster, which is shown to converge to the Brownian web

Diffusion Limited Aggregation with Power-Law Pinning

Using stochastic conformal mapping techniques we study the patterns emerging from Laplacian growth with a power-law decaying threshold for growth $R_N^{-\gamma}$ (where $R_N$ is the radius of the $N-$ particle cluster). For $\gamma > 1$ the growth pattern is in the same universality class as diffusion limited aggregation (DLA) growth, while for $\gamma < 1$ the resulting patterns have a lower fractal dimension $D(\gamma)$ than a DLA cluster due to the enhancement of growth at the hot tips of the developing pattern. Our results indicate that a pinning transition occurs at $\gamma = 1/2$, significantly smaller than might be expected from the lower bound $\alpha_{min} \simeq 0.67$ of multifractal spectrum of DLA. This limiting case shows that the most singular tips in the pruned cluster now correspond to those expected for a purely one-dimensional line. Using multifractal analysis, analytic expressions are established for $D(\gamma)$ both close to the breakdown of DLA universality class, i.e., $\gamma \lesssim 1$, and close to the pinning transition, i.e., $\gamma \gtrsim 1/2$.Comment: 5 pages, e figures, submitted to Phys. Rev.

New Algorithm for Parallel Laplacian Growth by Iterated Conformal Maps

We report a new algorithm to generate Laplacian Growth Patterns using iterated conformal maps. The difficulty of growing a complete layer with local width proportional to the gradient of the Laplacian field is overcome. The resulting growth patterns are compared to those obtained by the best algorithms of direct numerical solutions. The fractal dimension of the patterns is discussed.Comment: Sumitted to Phys. Rev. Lett. Further details at http://www.pik-potsdam.de/~ander

Conformal mapping methods for interfacial dynamics

The article provides a pedagogical review aimed at graduate students in materials science, physics, and applied mathematics, focusing on recent developments in the subject. Following a brief summary of concepts from complex analysis, the article begins with an overview of continuous conformal-map dynamics. This includes problems of interfacial motion driven by harmonic fields (such as viscous fingering and void electromigration), bi-harmonic fields (such as viscous sintering and elastic pore evolution), and non-harmonic, conformally invariant fields (such as growth by advection-diffusion and electro-deposition). The second part of the article is devoted to iterated conformal maps for analogous problems in stochastic interfacial dynamics (such as diffusion-limited aggregation, dielectric breakdown, brittle fracture, and advection-diffusion-limited aggregation). The third part notes that all of these models can be extended to curved surfaces by an auxilliary conformal mapping from the complex plane, such as stereographic projection to a sphere. The article concludes with an outlook for further research.Comment: 37 pages, 12 (mostly color) figure

Scaling exponent of the maximum growth probability in diffusion-limited aggregation

An early (and influential) scaling relation in the multifractal theory of Diffusion Limited Aggregation(DLA) is the Turkevich-Scher conjecture that relates the exponent \alpha_{min} that characterizes the ``hottest'' region of the harmonic measure and the fractal dimension D of the cluster, i.e. D=1+\alpha_{min}. Due to lack of accurate direct measurements of both D and \alpha_{min} this conjecture could never be put to serious test. Using the method of iterated conformal maps D was recently determined as D=1.713+-0.003. In this Letter we determine \alpha_{min} accurately, with the result \alpha_{min}=0.665+-0.004. We thus conclude that the Turkevich-Scher conjecture is incorrect for DLA.Comment: 4 pages, 5 figure

A Measurement of the Branching Fraction for the Inclusive B --> X(s) gamma Decays with the Belle Detector

We have measured the branching fraction of the inclusive radiative B meson decay B --> X(s) gamma to be Br(B->X(s)gamma)=(3.36 +/- 0.53(stat) +/- 0.42(sys) +0.50-0.54(th)) x 10^{-4}. The result is based on a sample of 6.07 x 10^6 BBbar events collected at the Upsilon(4S) resonance with the Belle detector at the KEKB asymmetric e^+e^- storage ring.Comment: 14 pages, 6 Postsript figures, uses elsart.cl

Deterministic mathematical modelling for cancer chronotherapeutics: cell population dynamics and treatment optimisation

Chronotherapeutics has been designed and used for more than twenty years as an effective treatment against cancer by a few teams around the world, among whom one of the first is Francis Lévi's at Paul-Brousse hospital (Villejuif, France), in application of circadian clock physiology to determine best infusion times within the 24-hour span for anticancer drug delivery. Mathematical models have been called in the last ten years to give a rational basis to such optimised treatments, for use in the laboratory and ultimately in the clinic. While actual clinical applications of the theoretical optimisation principles found have remained elusive so far to improve chronotherapeutic treatments in use, mathematical models provide proofs of concepts and tracks to be explored experimentally, to progress from theory to bedside. Starting from a simple ordinary differential equation model that allowed setting and numerically solving a drug delivery optimisation problem with toxicity constraints, this modelling enterprise has been extended to represent the division cycle in proliferating cell populations with different molecular targets, to allow for the representation of anticancer drug combinations that are used in clinical oncology. The main point to be made precise in such a therapeutic optimisation problem is to establish, here in the frame of circadian chronobiology, physiologically based differences between healthy and cancer cell populations in their responses to drugs. To this aim, clear biological evidence at the molecular level is still lacking, so that, starting from indirect observations at the experimental and clinical levels and from theoretical considerations on the model, speculations have been made, that will be exposed in this review of cancer chronotherapeutics models with the corresponding optimisation problems and their numerical solutions, to represent these differences between the two cell populations, with regard to circadian clock control

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome